AR041125A1 - Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprende - Google Patents
Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprendeInfo
- Publication number
- AR041125A1 AR041125A1 ARP030103176A ARP030103176A AR041125A1 AR 041125 A1 AR041125 A1 AR 041125A1 AR P030103176 A ARP030103176 A AR P030103176A AR P030103176 A ARP030103176 A AR P030103176A AR 041125 A1 AR041125 A1 AR 041125A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- heteroaryl
- heterocycloalkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 40
- 125000001072 heteroaryl group Chemical group 0.000 abstract 18
- 229910052736 halogen Inorganic materials 0.000 abstract 14
- 150000002367 halogens Chemical class 0.000 abstract 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 13
- 125000001424 substituent group Chemical group 0.000 abstract 13
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 125000001624 naphthyl group Chemical group 0.000 abstract 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 5
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- -1 -S (O) malkyl Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 108020004021 3-ketosteroid receptors Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000002978 peroxides Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41026102P | 2002-09-12 | 2002-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041125A1 true AR041125A1 (es) | 2005-05-04 |
Family
ID=31994096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103176A AR041125A1 (es) | 2002-09-12 | 2003-09-02 | Derivados sustituidos de 1,4- pirazina y composicion farmaceutica que los comprende |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040116444A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1539736A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2006506350A (cg-RX-API-DMAC10.html) |
| AR (1) | AR041125A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2003269949A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR0314139A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2494975A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA05002418A (cg-RX-API-DMAC10.html) |
| TW (1) | TW200503717A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2004024719A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05012082A (es) * | 2003-05-09 | 2006-02-22 | Pharmacia & Upjohn Co Llc | Compuestos como antagonistas del receptor crf1. |
| US20060211710A1 (en) * | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| IL311645B2 (en) * | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| PL3788049T3 (pl) | 2018-05-01 | 2023-06-19 | Revolution Medicines, Inc. | Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR |
| EP3788050B1 (en) | 2018-05-01 | 2024-08-28 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
| EP4531859A4 (en) | 2022-05-25 | 2026-05-27 | Revolution Medicines Inc | CANCER TREATMENT METHODS USING AN MTOR INHIBITOR |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4270297A (en) * | 1996-09-16 | 1998-04-02 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| PA8467401A1 (es) * | 1998-02-17 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para tratar la insuficiencia cardiaca |
| IL139197A0 (en) * | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
| ATE307121T1 (de) * | 2000-02-16 | 2005-11-15 | Neurogen Corp | Substituierte arylpyrazine |
-
2003
- 2003-08-27 EP EP03751841A patent/EP1539736A1/en not_active Withdrawn
- 2003-08-27 US US10/649,299 patent/US20040116444A1/en not_active Abandoned
- 2003-08-27 AU AU2003269949A patent/AU2003269949A1/en not_active Abandoned
- 2003-08-27 BR BR0314139-0A patent/BR0314139A/pt not_active IP Right Cessation
- 2003-08-27 CA CA002494975A patent/CA2494975A1/en not_active Abandoned
- 2003-08-27 MX MXPA05002418A patent/MXPA05002418A/es not_active Application Discontinuation
- 2003-08-27 JP JP2004536018A patent/JP2006506350A/ja not_active Abandoned
- 2003-08-27 WO PCT/US2003/024805 patent/WO2004024719A1/en not_active Ceased
- 2003-09-02 AR ARP030103176A patent/AR041125A1/es unknown
- 2003-09-10 TW TW092125064A patent/TW200503717A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20040116444A1 (en) | 2004-06-17 |
| TW200503717A (en) | 2005-02-01 |
| MXPA05002418A (es) | 2005-05-27 |
| BR0314139A (pt) | 2005-07-12 |
| CA2494975A1 (en) | 2004-03-25 |
| AU2003269949A1 (en) | 2004-04-30 |
| WO2004024719A1 (en) | 2004-03-25 |
| JP2006506350A (ja) | 2006-02-23 |
| EP1539736A1 (en) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| AR035532A1 (es) | Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos | |
| PE20011047A1 (es) | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| PE20020593A1 (es) | Activadores de glucocinasa del tipo isoindolin-2-ona | |
| AR041508A1 (es) | Compuestos con actividad en los receptores de glutamato metabotropicos | |
| AR048377A1 (es) | Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos | |
| AR016666A1 (es) | Derivados de pirimidinona, un procedimiento para su preparacion y una composicion farmaceutica que los contiene | |
| AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
| AR023152A1 (es) | Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion | |
| AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
| AR037355A1 (es) | Compuesto derivado de difenilamina, composicion farmaceutica y su uso en la fabricacion de medicamentos | |
| AR035695A1 (es) | Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| AR033306A1 (es) | Compuestos | |
| AR045582A1 (es) | Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1 | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| DK0447285T3 (da) | Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem | |
| AR038882A1 (es) | Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene | |
| PE20030269A1 (es) | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas | |
| CO5011090A1 (es) | Derivados de acil-piperazinil-pirimidinas, procedimiento para su preparacion y composiciones farmaceuticas de los mismos | |
| ES2253568T3 (es) | Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |